Bavencio® (avelumab) – New indication
May 14, 2019 - EMD Serono and Pfizer announced the FDA approval of Bavencio (avelumab), in combination with Inlyta® (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Download PDF
